Targeting Disease at the Nuclear Pore
Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer.

SINE Technology

Karyopharm is the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, developed to address a fundamental mechanism of oncogenesis.

Scientist doctor looking at sample in test tube

Pipeline

Our drug pipeline includes 4 unique investigational medicines targeting both hematologic malignancies and solid tumors.

Press Releases

June 19, 2019
Karyopharm Reports Updated Data from the Phase 2b SADAL Study at the 2019 International Conference on Malignant Lymphoma
June 14, 2019
Karyopharm Reports New and Updated Selinexor Combination Data from the Phase 1b/2 STOMP Study at the European Hematology Association 2019 Annual Meeting

Targeting Disease at the Nuclear PoreKaryopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer.

SINE Technology

Pipeline

Press Releases

Join The Karyopharm Team

Targeting Disease at the Nuclear Pore
Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer.